Curis Doses First Five Patients in TakeAim CLL Study
Go back to Curis Doses First Five Patients in TakeAim CLL Study| Curis, Inc. (NASDAQ: CRIS) | Delayed: 5.06 +0.08 (1.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.98 | 52 Week High | $3.70 | |||
| Open | $5.02 | 52 Week Low | $1.25 | |||
| Day High | $5.06 | P/E | N/A | |||
| Day Low | $5.02 | EPS | $-0.15 | |||
| Volume | 1,591 | |||||
